The Use of Herbs and Dietary Supplements in Gynecology:An Evidence-Based Review

Journal of Midwifery and Women's Health

Volumn 51, Issue 6, 2006, Pages 402-409

  Dennehy, Cathi E ^a  

^a NONE

Author keywords

dysmenorrhea; gynecology; herb; infertility; menopause; premenstrual; supplement

Indexed keywords

AGNOLYT; ALPHA TOCOPHEROL; ANGELICA SINENSIS EXTRACT; ASCORBIC ACID; CALCIUM; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; ESTRADIOL; ESTROGEN; FEMAPRIN; FLUOXETINE; FOLIC ACID; GINSENG EXTRACT; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; ICOSAPENTAENOIC ACID; IRON; ISOFLAVONE DERIVATIVE; KAVA EXTRACT; MAGNESIUM; MASTODYNON; PHYTOESTROGEN; PRIMROSE OIL; PYRIDOXINE; RED CLOVER EXTRACT; SELENIUM; THIAMINE; UNINDEXED DRUG; VITEX AGNUS CASTUS EXTRACT; ZINC;

ACNE; ALTERNATIVE MEDICINE; ANXIETY DISORDER; ARTICLE; CATARACT; CLINICAL TRIAL; CONSUMER; DIET SUPPLEMENTATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG UTILIZATION; DYSMENORRHEA; ENDOMETRIUM HYPERPLASIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FEMALE; FEMALE INFERTILITY; GYNECOLOGY; HERBAL MEDICINE; HOT FLUSH; HUMAN; HYPOMANIA; INSOMNIA; LIVER DYSFUNCTION; MANIA; MASTALGIA; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; MIDWIFE; MOOD CHANGE; PATIENT CARE; PHOTOSENSITIVITY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RESTLESSNESS; SEROTONIN SYNDROME; STOMACH DISEASE; SWEAT GLAND DISEASE;

DIETARY SUPPLEMENTS; DYSMENORRHEA; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFERTILITY, FEMALE; LIFE STYLE; MENOPAUSE; MENORRHAGIA; MENSTRUATION DISTURBANCES; MIDWIFERY; PHYTOTHERAPY; PLANTS, MEDICINAL; PREMENSTRUAL SYNDROME; RANDOMIZED CONTROLLED TRIALS; WOMEN'S HEALTH;

EID: 33750346323     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmwh.2006.01.004     Document Type: Article

References (56)

1. Institute of Medicine of the National Academics. Complementary and alternative medicine in the United States (2005), National Academics Press, Washington, DC
2. Kelly J.P., Kaufman D.W., Kelley K., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent trends in use of herbal and other natural products. Arch Intern Med 165 (2005) 281-286
3. McFarlin B.L., Gibson M.H., O'Rear J.O., and Harman P. A national survey of herbal preparation use by nurse midwives for labor stimulation. J Nurse-Midwifery 44 (1999) 205-216
4. In: Blumenthal M., Goldberg A., and Brinckmann J. (Eds). Herbal medicine: Expanded German Commission E monographs (2000), Integrative Medicine Communications, Newton, MA
5. Borelli F., and Ernst E. Cimicifuga racemosa: A systematic review of its clinical efficacy. Eur J Clin Pharmacol 58 (2002) 235-241
6. Liske E., Hanggi W., Henneicke-Von Zepplin H.H., Boblitz N., Wustenberg P., Rahlfs V.W., et al. Physiological investigation of a unique extract of black cohosh (Cimicifuge racemosae rhizome): A 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gender Based Med 11 (2002) 163-174
7. Burdette J.E., Liu J., Chen S., Fabricant D.S., Piersen C.E., Barker E.L., et al. Black cohosh as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 51 (2003) 5661-5670
8. Jarry H., Metten M., Spengler B., Christoffel V., and Wuttke W. In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas 44 (2003) S31-S38
9. Seidlova-Wuttke D., Hesse O., Jarry H., Christoffel V., Spenfler B., Becker T., et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: Comparison with estradiol-17B. Eur J Endocrinol 149 (2003) 351-362
10. Bodinet C., and Freudenstein J. Influence of marketed herbal menopause preparations on MCF-7 cell proliferation. Menopause 11 (2004) 281-289
11. Fox M. Researchers: Popular menopause herb may worsen cancer. Reuters [Internet] July 12, 2003. Available from: http://www.cancerpage.com/news/about.asp?id=1 [Accessed July 15, 2005].
12. Osmers R., Friede M., Liske E., Schnitker J., Freudenstein J., and Henneicke-von Zeplin H.H. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Am Coll Obstet Gynecol 105 (2005) 1074-1083
13. Nappi R.E., Malavasi B., Brunu B., and Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: A randomized study versus low dose transdermal estrogen. Gynecol Endocrinol 20 (2005) 30-35
14. Wuttke W., Seidlova-Wuttke D., and Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in double-blind, placebo-controlled study: Effects on menopause symptoms and bone markers. Maturitas 44 (2003) S67-S77
15. Jacobsen J.S., Troxel A.B., Evans J., Klaus L., Vahdat L., Kinne D., et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 19 (2001) 2739-2745
16. Hernandez Munoz G., and Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 44 Suppl 1 (2003) S59-S65
17. Huntley A., and Ernst E. A systematic review of the safety of black cohosh. Menopause 10 (2003) 58-64
18. Tsukamoto S., Aburatani M., and Ohta T. Isolation of CYP3A4 inhibitors from black cohosh (Cimicifuga racemosa). Evid-Based Complement Altern Med 2 (2005) 223-226
19. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry B., Khan I.A., et al. In vivo effects of goldenseal, kava kava, black cohosh and valerian on human cytochrome P450, 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77 (2005) 415-426
20. Albertazzi P., and Purdie D.W. The nature and utility of phytoestrogens: A review of the evidence. Maturitas 42 (2002) 173-185
21. Jellin J.M., Gregory P., Batz F., Hitchens K., Burson S., Shaver K., et al. Pharmacist's letter/prescriber's letter natural medicines comprehensive database. 3rd ed (2000), Therapeutic Research Facutly, Stockton, CA
22. Krebs E.E., Ensrud K.E., MacDonald R., and Wilt T. Phytoestrogens for treatment of menopausal symptoms: A systematic review. Obstet Gynecol 104 (2004) 824-836
23. Unfer V., Casini M.L., Costabile L., Mignosa M., Gerli S., and Di Renzo G.C. Endometrial effects of long term treatment with phytoestrogens: A randomized, double-blind, placebo-controlled study. Fertil Steril 82 (2004) 145-148
24. Huntley A.L., and Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 10 (2003) 465-476
25. Kronenberg F., and Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: A review of randomized, controlled trials. Ann Intern Med 137 (2002) 805-813
26. Grube B., Walper A., and Wheatley D. St John's wort extract: Efficacy for menopausal symptoms of psychological origin. Adv Ther 16 (1999) 177-186
27. Clouatre D.L. Kava kava: Examining new reports of toxicity. Toxicol Lett 150 (2004) 85-96
28. Proctor M.L., and Murphy P.A. Herbal and dietary therapies for primary and secondary dysmenorrhea. Cochrane Database Syst Rev 2 (2001) CD002124
29. Sales K.J., and Jabbour N. Cyclooxygenase and prostaglandins in pathology of the endometrium. Reproduction 126 (2003) 559-567
30. Low Dog T. Conventional and alternative treatments for endometriosis. Altern Ther 7 (2001) 50-57
31. Hudgins A.P. Vitamins P, C and niacin for dysmenorrheal therapy. West J Surg Obstet Gynecol 62 (1954) 610-611
32. Fugh-Berman A., and Kronenberg F. Complementary and alternative medicine (CAM) in reproductive age women: A review of randomized controlled trials. Reprod Toxicol 17 (2003) 137-152
33. Ziaei S., Zakeri M., and Kazemnejad A. A randomized controlled trial of vitamin E in the treatment of primary dysmenorrheal. BJOG 112 (2005) 466-469
34. Gokhale L.B. Curative treatment of primary (spasmodic) dysmenorrhea. Ind J Med Res 103 (1996) 227-231
35. Blanche Butler E., and McKnight E. Vitamin E in the treatment of primary dysmenorrhea. Lancet 268 (1955) 844-847
36. Ziaei S., Faghihzadeh S., Sohrabvand F., Lamyian M., and Ememgholy T. A randomized placebo-controlled trial to determine the efficacy of vitamin E in treatment of primary dysmenorrhea. Br J Obstet Gynaecol 108 (2001) 1181-1183
37. Ford E.S., Ajani U.A., and Mokdad A.H. Brief communication: The prevalence of high intake of vitamin E from the use of supplements among US adults. Ann Intern Med 29 5 Suppl 1 (2005) 31-35
38. Blatt D.H., Pryor W.A., Mata J.E., and Rodriguez-Proteau R. Re-evaluation of the relative potency of synthetic and natural alpha-tocopherol: Experimental and clinical observations. J Nutr Biochem 15 (2004) 380-395
39. Saldeen P., and Saldeen T. Women and omega-3 fatty acids. Obstet Gynecol Surv 59 (2004) 722-730
40. Bertone-Johnson E.R., Hankinson S.E., Bendich A., Johnson S.R., Willett W.C., and Manson J.E. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med 165 (2005) 1246-1252
41. Gately C.A., and Mansel R.E. Management of the painful and nodular breast. Br Med Bull 47 (1991) 284-294
42. Halaska M., Beles P., Gorkow C., and Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: Results of a placebo-controlled double-blind study. Breast 8 (1999) 175-181
43. Wuttke W., Splitt G., Gorkow C., and Sieder C. Treatment of cyclical mastalgia: Results of a randomized, placebo-controlled, double-blind study. (abstract in English). Geburtshilfe und Frauenheilkunde 57 (1997) 569-574
44. Kubista E., Muller G., and Spona J. Treatment of mastopathies with cyclic mastodynia: Clinical results and hormonal profiles. (abstract in English). Rev Fr Gynecol Obstet 82 (1987) 221-227
45. Medicines and Healthcare Products Regulatory Agency. What's new: Epogam and Efamast (gamalinolenic acid)-Withdrawal of marketing authorizations (2002). http://www.medicines.mhra.gov.uk/whatsnew/epogam.htm [Internet]. August 10. Available from: http://www.medicines.mhra.gov.uk/whatsnew/epogam.htm [Accessed July 15, 2005]
46. Goyal A., and Mansel R.E. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast 11 (2005) 41-47
47. Wyatt K.M., Dimmock P.W., Frischer M., Jones P.W., and O'Brien S. Prescribing patterns in premenstrual syndrome. BMC Womens Health 2 (2002) 4
48. Wuttke W., Jarry H., Christoffel B., Spengler B., and Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)-Pharmacology and clinical indications. Phytomed 10 (2003) 348-357
49. Turner S., and Mills S. A double-blind clinical trial on a herbal remedy for premenstrual syndrome: A case study. Complement Ther Med 1 (1993) 73-77
50. Atmaca M., Kumru S., and Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol Clin Exp 18 (2003) 191-195
51. Daniele C., Thompson Coon J., Pittler M.H., and Ernst E. Vitex agnus castus: A systematic review of adverse effects. Drug Saf 28 (2005) 319-332
52. Henmi H., Endo T., Kitajima Y., Manase K., Hata H., and Kudo R. Effects of ascorbic acid supplementation on serum progesterone levels in patients with luteal phase defect. Fertil Steril 80 (2003) 459-461
53. Gerhard I.I., Patek A., Monga B., Blank A., and Gorkow C. Mastodynon for female sterility. (abstract in English). Forsch Komplementarmed 5 (1998) 272-278
54. Westphal L.M., Polan M.L., Trant A.S., and Moone S.B. A nutritional supplement for improving fertility in women. J Reprod Med 49 (2004) 289-293
55. Battaglia C., Regnani G., Marsella T., Facchinetti F., Volpe A., Venturoli S., et al. Adjuvant L-arginine treatment in controlled ovarian hyperstimulation: A double-blind, randomized study. Hum Reprod 17 (2002) 659-665
56. Consumer Lab. Available from: www.consumerlab.com [Accessed July 30, 2005].